Polymerase News and Research

RSS

Bristol-Myers Squibb terminates BMS-986094 Phase II development for treatment of hepatitis C

Bristol-Myers Squibb Company announced today that the Company has discontinued development of BMS-986094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor that was in Phase II development for the treatment of hepatitis C.

24 Aug 2012

Live bacteria in more than 90% of middle ear effusions

Live bacteria are present in more than 90% of middle ear effusions, research shows.

20 Aug 2012

New England Biolabs releases Q5 High-Fidelity DNA Polymerase

New England Biolabs (NEB) has released a novel DNA polymerase, Q5 High-Fidelity DNA Polymerase, that provides the highest fidelity amplification currently available, while also offering robust amplification across the broadest range of amplicons, including those that are GC- and AT-rich.

From New England Biolabs 9 Aug 2012

Clovis Oncology reports net loss of $15.7 million for second quarter 2012

Clovis Oncology, Inc. today reported financial results for the second quarter 2012, and provided an update on the progress of its clinical development programs and expected milestones for the rest of the year.

8 Aug 2012

Clovis Oncology, Foundation Medicine enter diagnostic collaboration

Foundation Medicine, Inc. and Clovis Oncology, Inc. announced today that they have entered into a diagnostic collaboration.

6 Aug 2012

Drug molecules designed for influenza may be adapted to treat other viruses

St. Jude Children's Research Hospital study shows how compounds blocking an enzyme universal to all influenza viruses may allow development of new antiviral drugs that also avoid the problem of drug resistance

3 Aug 2012

Population Genetics validates GenomePooling™ for cancer

Population Genetics Technologies Ltd., creator of innovative methods for genetic analyses and biomarker discovery, has successfully completed a pilot study to prove that its GenomePooling™ method is sensitive and accurate enough to detect even small percentages of gene variants within cancer tissue. This validates the method’s suitability for use in IntReALL 2010, the world’s largest genetic analysis of acute lymphoblastic leukaemia (ALL) relapse cases. ALL is the most common childhood malignant disease.

31 Jul 2012

GenomePooling™ method is sensitive and accurate

31 Jul 2012

Parkinson’s disease treatment: an interview with Ted Dawson

Parkinson’s disease is a disorder which usually affects people in their 60’s and older. It is caused by the loss of dopamine neurons in the brain leading to rigidity, slowness of movement, tremor, problems with balance and so forth.

31 Jul 2012

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

ARIAD Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult patients with newly diagnosed chronic myeloid leukemia (CML).

28 Jul 2012

Single-step method can rapidly detect pathogens and chemical contaminants

Using nanoscale materials, researchers at the University of Georgia have developed a single-step method to rapidly and accurately detect viruses, bacteria and chemical contaminants.

20 Jul 2012

Abbott to showcase new informatics and lab solutions at AACC annual meeting

Abbott will feature new solutions to improve data management and automation at this year's American Association for Clinical Chemistry (AACC) annual meeting, July 15-19, in Los Angeles, Calif. Solutions to further enhance efficiency and workflow in today's laboratories will be the focal point of the Abbott exhibit.

16 Jul 2012

PCR assay ‘superior’ to culture for neonatal sepsis, meningitis

In neonates with probable sepsis or meningitis, a realtime polymerase chain reaction assay specific for a virulence gene in Streptococcus agalactiae is superior to standard bacterial culture identification, results of a pathology study show.

11 Jul 2012

Microbiologists reveal how T. brucei’s key proteins organize to replicate its mtDNA

A group of diseases that kill millions of people each year can't be touched by antibiotics, and some treatment is so harsh the patient can't survive it. They're caused by parasites, and for decades researchers have searched for a "magic bullet" to kill them without harming the patient. Now, a team of microbiologists at the University of Massachusetts Amherst has made an advance that could one day lead to a new weapon for fighting parasitic diseases such as African sleeping sickness, chagas disease and leishmaniasis.

11 Jul 2012

Cylene's Pol I inhibitor activates p53 and selectively destroys cancer cells

Cylene Pharmaceuticals today announced that research collaborators at the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia have established, for the first time, that RNA Polymerase I (Pol I) activity is essential for cancer cell survival and that its inhibition selectively activates p53 to kill tumors. Published today in Cancer Cell, the findings show that Cylene's Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant but not in normal cells.

11 Jul 2012

Blocking a fundamental process deep within cancer cells can selectively kill them

Investigators reporting in the July issue of the Cell Press journal Cancer Cell have found that blocking a fundamental process deep within cancer cells can selectively kill them and spare normal cells.

10 Jul 2012

PCV13 offers best overall protection from CAP in young children

Researchers have identified a pneumococcal conjugate vaccine that is effective for treating bacteremic pneumococcal community-acquired pneumonia in children aged 5 years or younger.

9 Jul 2012

Gene vital to flu severity discovered

Researchers have discovered that a protein known as PA-X, produced from a ribosomal frameshift mutation in a gene in the influenza A genome, has a substantial impact on host response to the virus.

2 Jul 2012

AASLD, EASL to hold special conference on therapy of HCV

The European Association for the Study of the Liver (EASL), together with the American Association for the Study of Liver Diseases (AASLD), will be holding an exciting "Special Conference" dedicated to the timely topic of: Therapy of Hepatitis C: Clinical Application and Drug Development.

29 Jun 2012

FDA approves test for dengue virus infection

The first test that can detect the presence of the dengue virus itself rather than antibodies to the virus has been approved for use by the US Food and Drug Administration.

27 Jun 2012